Castleman's disease--a two compartment model of HHV8 infection
- PMID: 20603649
- DOI: 10.1038/nrclinonc.2010.103
Castleman's disease--a two compartment model of HHV8 infection
Abstract
Castleman's disease is a primary infectious disease of the lymph node that causes local symptoms or a systemic inflammatory syndrome. Histopathology reveals a destroyed lymph node architecture that can range from hyaline-vascular disease to plasma-cell disease. Viral interleukin 6 (vIL-6) produced during the replication of human herpesvirus type 8 (HHV8) is the key driver of systemic inflammation and cellular proliferation. Stage progression of Castleman's disease results from switches between viral latency and lytic replication, and lymphatic and hematogenous spread. Multicentric plasma-cell disease in HIV-1 patients is associated with HHV8 infection. Polyclonal plasmablast proliferation escapes control in the germinal center with eventual malignant transformation into non-Hodgkin lymphoma. Surgery produces excellent results in unicentric disease, while multicentric disease responds to anti-CD20 therapy or IL-6 and chemotherapy. Lymphovascular endothelium and naive B cells are infectious reservoir-opening options for antiangiogenic and anti-CD19 strategies to enhance outcomes in patients with systemic disease.
Similar articles
-
Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.Leuk Lymphoma. 2000 Jul;38(3-4):387-94. doi: 10.3109/10428190009087030. Leuk Lymphoma. 2000. PMID: 10830746 Review.
-
Human herpesvirus 8 and Epstein-Barr virus-related monotypic large B-cell lymphoproliferative disorder coexisting with mixed variant of Castleman's disease in a lymph node of a renal transplant recipient.Clin Transplant. 2003 Oct;17(5):451-4. doi: 10.1034/j.1399-0012.2003.00098.x. Clin Transplant. 2003. PMID: 14703929
-
Treatment of Castleman's disease.Curr Treat Options Oncol. 2005 May;6(3):255-66. doi: 10.1007/s11864-005-0008-z. Curr Treat Options Oncol. 2005. PMID: 15869736 Review.
-
Dissolution of the lymphoid follicle is a feature of the HHV8+ variant of plasma cell Castleman's disease.Am J Surg Pathol. 2003 Jan;27(1):91-100. doi: 10.1097/00000478-200301000-00010. Am J Surg Pathol. 2003. PMID: 12502931
-
Kaposi's sarcoma herpesvirus-associated Castleman's disease with POEMS syndrome.Muscle Nerve. 2000 Mar;23(3):436-9. doi: 10.1002/(sici)1097-4598(200003)23:3<436::aid-mus18>3.0.co;2-i. Muscle Nerve. 2000. PMID: 10679723
Cited by
-
18F-FDG PET/CT metabolic parameters are correlated with clinical features and valuable in clinical stratification management in patients of castleman disease.Cancer Imaging. 2025 Feb 12;25(1):12. doi: 10.1186/s40644-025-00833-9. Cancer Imaging. 2025. PMID: 39940060 Free PMC article.
-
Does Kaposi's sarcoma predict multicentric Castleman disease in the presence of generalized lymphadenopathy?Med Oncol. 2012 Jun;29(2):1109-13. doi: 10.1007/s12032-011-9886-z. Epub 2011 Apr 7. Med Oncol. 2012. PMID: 21472488
-
Multicentric Castleman Disease of the Supraglottis: A Surgeons' Dilemma.Iran J Otorhinolaryngol. 2023 Mar;35(127):101-108. doi: 10.22038/IJORL.2023.57806.2995. Iran J Otorhinolaryngol. 2023. PMID: 37223400 Free PMC article.
-
[Dyspnoea, cough and B symptoms in a 40-year-old woman].Internist (Berl). 2013 Aug;54(8):1011-5. doi: 10.1007/s00108-013-3327-3. Internist (Berl). 2013. PMID: 23836253 German.
-
The role of IL-6 in host defence against infections: immunobiology and clinical implications.Nat Rev Rheumatol. 2017 Jul;13(7):399-409. doi: 10.1038/nrrheum.2017.83. Epub 2017 Jun 15. Nat Rev Rheumatol. 2017. PMID: 28615731 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical